Spero Reports Preliminary Findings From Phase 1 Clinical Trial Of SPR206 Suggesting It Is Well-Tolerated At Doses Within Therapeutic Range For Target And Plans To Advance Program With Alliance Partners Everest Medicines And The Department Of Defense

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO),amulti-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high

Benzinga · 01/13/2020 13:07

CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO),amulti-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases,today announced preliminary findings from its Phase 1 first-in-humansclinicaltrial of SPR206, an IV-administered product candidate being developed by Spero as an innovative option to treat MDR Gram-negative bacterial infections.
 

Analysis of preliminary, blinded data from the Phase 1 double-blind, placebo-controlled singleascending dose (SAD)and multiple ascending dose(MAD) clinicaltrialin healthy adult volunteers suggests that SPR206iswell-tolerated at doses that are likely to be within a therapeutic range for target MDR Gram-negative bacterial infections and has asafety profile that Spero believes supports the further development of SPR206. The decision to continue development of SPR206 is also supported by data from nonclinical studies in which SPR206 demonstrated activity as a single agent against MDR and extensively drug resistant (XDR) bacterial strains, including isolates ofPseudomonas aeruginosa,Acinetobacter baumanniiand carbapenem-resistantEnterobacteriaceae, in bothin vitroandin vivomodels of infection.